ELTX: Strong immune activity supports testing combinations, though Phase II missed its primary DFS endpoint

Elicio Therapeutics' AMPLIFY-7P trial showed T-cell activation and favorable subgroup signals but missed its primary DFS endpoint. The company plans further trials to test combinations and refine patient selection, according to a KOL event transcript.

Original reporting
Published Nov 11, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 12:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ELTX: Strong immune activity supports testing combinations, though Phase II missed its primary DFS endpoint — source image
Decision brief

The 30-second read

$ELTXBearishMed
01

Why it matters

The miss introduces uncertainty about the drug's efficacy, likely prompting a short‑term price decline.

02

Market read

New clinical trial data for a micro‑cap biotech, relevant for traders tracking biotech trial outcomes.

03

What to watch

Future combination trials could mitigate the negative impact.

Relevance 8/10Novelty 8/10Timing: today

Background

Elicio Therapeutics presented data from its AMPLIFY-7P trial, showing T‑cell activation but missing the primary disease‑free survival endpoint.

Company-level read

Ticker impact

$ELTXBearishHigh confidence
Context

Phase II trial missed its primary DFS endpoint, providing new clinical data for Elicio Therapeutics.

Expected impact

downward pressure as investors price in the missed endpoint

Evidence & confidence

First disclosure of a missed primary endpoint typically triggers sell‑offs in biotech stocks.

Market effects

May dampen sentiment for similar oncology/immune‑therapy peers.

Limited to US biotech sector.

Low; impact confined to niche biotech investors.

Counterpoint

If subgroup signals are strong, the miss may be viewed as a temporary setback.

Key entities

  • Elicio Therapeutics, Inc.

    Biotech firm developing immune‑based therapies.

Related articles

$ELTXHigh

Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • AMPLIFY-7P Phase 2 pre-specified analyses demonstrate substantial reductions in risk of recurrence or death in ctDNA negative patients and patients without prior radiation, enabling a

$ELTXHighAI 8/10

Elicio’s pancreatic cancer vaccine misses primary endpoint

Elicio Therapeutics (ELTX) reported that its Phase 2 study of camupepimut for pancreatic cancer did not meet the primary endpoint of disease-free survival. The study had a hazard ratio of 0.85, missing the target. Subgroup analyses showed potential benefits in patients without baseline ctDNA positivity. The company plans to discuss findings with the FDA for a potential Phase 3 study.

$ELTXMedAI 9/10

99% of evaluable treated patients showed immune responses to a cancer mutation. The trial missed its main goal.

Elicio Therapeutics (ELTX) reported Phase 2 trial results for camupepimut (ELI-002 7P) in pancreatic cancer, missing the primary DFS endpoint but showing favorable trends in subgroups. Key findings: 99% of patients showed immune responses, and DFS improvements were observed in ctDNA-negative (HR 0.51) and ctDNA-positive (HR 0.57) patients. The company plans to discuss Phase 3 study design with the FDA.

$ELTXLow

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an a